| ATC | Anaplastic thyroid cancer |
| anti-CTLA-4 | anti-cytotoxic T lymphocyte antigen 4 |
| anti-PD-1 | anti-programmed cell death protein-1 |
| anti-PD-L1 | anti-programmed cell death ligand-1 |
| BRAF | B-Raf (rapidly accelerated fibrosarcoma) proto-oncogene/threonine protein kinase B- |
| CAMP | 3′,5′-cyclic adenosine monophosphate |
| CH | congenital hypothyroidism |
| DIABLO | Diablo homolog |
| DTC | Differentiated thyroid cancer |
| EBV | Epstein–Barr Virus |
| FGF2 | Fibroblast Growth Factor 2 |
| FOXE1 | transcription factor Forkhead box E |
| FTC | Follicular thyroid cancer |
| GD | Graves’ Disease |
| HUVECs | Human umbilical vein endothelial cells |
| IC | immune checkpoints |
| MKI(s) | Multi-kinase inhibitor(s) |
| MTC | Medullary thyroid cancer |
| PROX1 | Prospero homeobox 1 |
| PTC | Papillary thyroid cancer |
| RAI | Radioiodine |
| SMAC | second mitochondria-derived activator of caspases |
| TC | Thyroid cancer |
| TKIs | Tyrosine-kinase inhibitor(s) |
| TSH | Thyroid-stimulating hormone |
| TSHB | Thyroid-stimulating hormone beta |
| TSHR | Thyroid-stimulating hormone receptor |
| TUSC2 | Tumour Suppressor Candidate 2 |